Clinical Trials Browser

INDUSTRY × ulocuplumab × Plasma cell × Clear all

NCT01359657 2016-03-16

Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma

Phase 1 Completed

Multiple Myeloma, Recurrence